TY - JOUR T1 - Facial Erythema of Rosacea - Aetiology, Different Pathophysiologies and Treatment Options. AU - Steinhoff,Martin, AU - Schmelz,Martin, AU - Schauber,Jürgen, PY - 2015/12/31/entrez PY - 2015/12/31/pubmed PY - 2017/1/18/medline SP - 579 EP - 86 JF - Acta dermato-venereologica JO - Acta Derm Venereol VL - 96 IS - 5 N2 - Rosacea is a common chronic skin condition that displays a broad diversity of clinical manifestations. Although the pathophysiological mechanisms of the four subtypes are not completely elucidated, the key elements often present are augmented immune responses of the innate and adaptive immune system, and neurovascular dysregulation. The most common primary feature of all cutaneous subtypes of rosacea is transient or persistent facial erythema. Perilesional erythema of papules or pustules is based on the sustained vasodilation and plasma extravasation induced by the inflammatory infiltrates. In contrast, transient erythema has rapid kinetics induced by trigger factors independent of papules or pustules. Amongst the current treatments for facial erythema of rosacea, only the selective α2-adrenergic receptor agonist brimonidine 0.33% topical gel (Mirvaso®) is approved. This review aims to discuss the potential causes, different pathophysiologies and current treatment options to address the unmet medical needs of patients with facial erythema of rosacea. SN - 1651-2057 UR - https://www.unboundmedicine.com/medline/citation/26714888/Facial_Erythema_of_Rosacea___Aetiology_Different_Pathophysiologies_and_Treatment_Options_ DB - PRIME DP - Unbound Medicine ER -